Human Research Protections in 2008: The View from 30,000 ft. Daniel Nelson Outgoing Member, SACHRP Co-Chair, Subpart A Subcommittee Presentation to the.

Slides:



Advertisements
Similar presentations
Ensuring Ethical Use of Quality Improvement Mary Ann Baily, PhD HIVQUAL US Advisory Committee Meeting August 24, 2008.
Advertisements

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
TISSUE BANKING Challenging to Say the Least
QI project or research? Thomas F. Byrd M.D. HRRC Chair Subcommitees 2 and 4 December 3, 2013.
Marian University is sponsored by the Sisters of St. Francis, Oldenburg. Human Subjects Research and the Marian University Institutional Review Board (IRB)
1  July 26, 2011  60 day public comment period ends: Monday, October 26, 2011 !! Paul J. Reitemeier, Ph.D., Chair Human Research Review Committee Note:
THE UW HEALTH SCIENCES IRB S OVERVIEW PRACTICAL REGULATORY ISSUES IN HUMAN SUBJECTS RESEARCH.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
The IRB Process Tony Medure, M.A., CIP, RAC Vanderbilt Human Research Protection Program.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
IRB 101: Introduction to Human Subject Research
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
CUMC IRB Investigator Meeting November 9, 2004 Research Use of Stored Data and Tissues.
The Role of IRBs in Ensuring Ethical Conduct of QI Activities Mary Ann Baily, PhD Columbia IRB Conference April 1, 2011.
Module 2 Sealy Center on Aging What kinds of scholarly products can I produce?
Ethical Principles of Human Subjects Protection
Central IRBs: Ceding IRB Oversight
Lisa Denney, MPH HRPP Assistant Director Melanie Mace, MA HRPP Education and Training Coordinator Bill Woods, PhD CAPS Policy and Ethics Core November.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
IRB and the Community Member How You Can Get Involved Mary Lou Smith Elda Railey Conference Call Series on IRBs and Ethical Issues in Research Co-sponsored.
Unit 6: Training and Supervision # Warm Up Questions: Instructions  Take five minutes now to try the Unit 6 warm up questions in your manual. 
A. Short term problems / considerations b. Long term mission View of human subjects protection system: SACHRP July 2008 Elizabeth Bankert.
Primary Care and Community Outreach Research VCOM Institutional Review Board Jim Mahaney, PhD Associate Dean for Biomedical Affairs, Virginia Campus Past.
Submitting IRB Applications (or “Do I have to do an IRB?”) Linda A. Detman, Ph.D. Research Associate Lawton & Rhea Chiles Center for Healthy Mothers and.
Secretary’s Advisory Committee on Human Subjects Protections (SACHRP) Summary of Responses on: Advanced Notice of Proposed Rulemaking (ANPRM) on Holding.
CONFLICTS OF INTEREST ARE HERE TO STAY: PROTECTING SCIENCE FROM BIAS Susan S. Ellenberg, Ph.D. Center for Biologics Evaluation and Research, FDA Boston,
Teaching Research Methods (Classroom Protocols) Boston University Charles River Campus Boston University Medical Center Mary A. Banks BS, BSN IRB Director.
Effectiveness in Review & Oversight of Human Subjects Research Steven Joffe, MD, MPH Assistant Professor of Pediatrics.
Yale Center for Clinical Investigation: Academic Home to the CTSA Secretary’s Advisory Committee on Human Research Protections (SACHRP) Presentation Tesheia.
Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators Advanced Notice.
Practical issues in IRB review Bernard Lo, M.D. August 16 and 19,
The Linguistics Department Institutional Review Board Committee Silvina Montrul, chair Fred Davidson Irene Koshik Ryan Shosted September 22, 2008.
SUNY Oswego Human Subjects Committee Last Revised 10/28/2011.
Human Subjects Research at ASU An Overview. Overview Definitions Historical Framework Federal Guidelines Human Subjects Research at ASU.
Status of SACHRP Recommendations July 2003-October 2008 Meeting of the Secretary’s Advisory Committee on Human Research Protections October 27, 2008 Michael.
Marian University is sponsored by the Sisters of St. Francis, Oldenburg. Human Subjects Research and the Marian University Institutional Review Board (IRB)
Ethics Review Committee | 28 th -30 th June 2009, Chengdu 1 |1 | The purpose and process of formal ethical review International Workshop of Ethics Review.
Human Subjects Research Office of Responsible Research Practices Human Subjects Research Vanessa Hill, MSHS, CCRC Senior Quality Improvement Specialist.
Wisconsin IRB Consortium (WIC): a model for multi-site IRB review Nichelle Cobb, PhD Director, Health Sciences IRBs University of Wisconsin-Madison Secretary’s.
$100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 Terms Clinical Trial Facts.
SACHRP PANEL: HOLDING EXTERNAL IRBS ACCOUNTABLE David L. Wynes, Ph.D. Vice President for Research Administration Emory University July 21, 2009.
Case Studies: Puzzles in Human Research Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst, Program for Research Integrity Development and Education.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
Understanding Clinical Trials – Part 2 Georgianne Arnold, MD Professor of Pediatrics University of Pittsburgh Medical Center Pittsburgh Children’s Hospital.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.
Regulatory Guidance for Genetic Testing. Three Specific Areas Laboratory tests Results of genetic testing – Clinical – Research GenomeWide Association.
Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.
Human Research Protection Program 101 March 20, 2007 Cincinnati, OH.
PRIMER: Human Subjects, Past, Present, and Future Susan Metosky, Arizona State University Debra Murphy, Arizona State University.
Research Ethics Office of Research Compliance. Responsible Conduct of Research (RCR) Covers 9 content areas –Animal Subjects (IACUC) –Human Subjects (IRB)
0 Ethics Lecture Research. ACADEMY OF OPHTHALMOLOGY Disclosures  The speaker has no financial interest in the subject matter of this.
Christine Yalda, J.D., Ph.D. Chair, Human Research Review Committee Grand Valley State University.
The IRB and Human Subjects Research Protection Eric Felde, CIP Research Compliance Consultant Office of Research Compliance Indiana University.
What is exempt research? Angela Bain, IRB Administrator
Back to Basics – Approval Criteria
Patricia M. Alt, Ph.D. Dept. of Health Science Towson University
Risk Determinations and Research with Children
NIH Clinical Trial Requirements
Overview - Introduction
Overview - Introduction
USC Institutional Review Boards
George Alter ICPSR Institute for Social Research
Overview of Changes to Human Subjects Research Regulations
The 2018 Human Subject Rules
Ethical Considerations for Pediatric Clinical Investigations
What the IRB is looking for when reviewing your protocol
Changes to the Common Rule and Single IRB (sIRB)
Common Rule
Research with Human Subjects
Presentation transcript:

Human Research Protections in 2008: The View from 30,000 ft. Daniel Nelson Outgoing Member, SACHRP Co-Chair, Subpart A Subcommittee Presentation to the Secretary’s Advisory Committee on Human Research Protections (SACHRP) July 16, 2008

How many angels can dance on the head of a pin? With apologies to Thomas Aquinas

This should not be what we’re all about!

Put another way… We spend too much time drowning in the details, and not enough time at 30,000 ft... or at least above sea level

Patchwork Quilt of Regulations…or… The Common Rule is Not Truly Common FDA Federally Funded (OHRP) Voluntary Application of Common Rule Unregulated Research HIPAA

“When you’ve seen one IRB… you’ve seen one IRB” IRBs are especially prone to “the one right way to do things” There may often be more than one right way, but that doesn’t mean they all need to be practiced… simultaneously, interchangeably, contradictorily We should minimize variability where possible, without sacrificing flexibility Consent form templates, common application forms, definitional interpretations

Alternative Models for an Evolving Research Environment (I) Research enterprise (esp. clinical research environment) has evolved considerably since 1970s Oversight system has failed to evolve to keep pace with volume, complexity and nature of research it oversees Research approaches increasingly do not fit neatly into current/traditional models of oversight Biobanking Population-wide studies Internet research International collaborations Multicenter trials

Alternative Models for an Evolving Research Environment (II) “Single site systems in a multi-center world” Predicated on local review of single sites Multi-center protocol is effectively a take-it-or- leave-it proposition for individual sites No effective means to modify underlying issues But… 300 versions of the “perfect consent form” Ineffective oversight of study-wide issues by patchwork quilt of independent sites AE reporting  example of positive reform

Mission Creep Combination of factors Uncertainty in applying definition(s) of Human Subjects Research Well-intended overreaching If a little protection is good, shouldn’t a lot of protection be better? After all, the IRB has an important job, with a lot riding on it! What is the harm in erring on the side of reviewing things that might technically fall outside those (admittedly blurry) lines? No one else to do it  give it to the IRB IRBs don’t do well with review/oversight of activities that are not Human Subjects Research

Ripe for Mission Creep? Athletics Administration Maintenance Garbage Clinical Care Education QI Human Subjects In Vitro Animal Subjects Case Reports Research Finance Policy Surveys Clinical Trials Observational

What requires IRB review? Where should the lines be drawn, in separating “Human Subjects Research” from activities that do not require IRB review… Quality improvement? Case reports? Classroom projects? De-identified specimens or data? Public health surveillance or interventions? Innovative clinical care? Key informant interviews about programmatic or organizational issues? Training or center grants? Other?

Why do we assume the worst? A system (or at least interpretations and practices) based on worst case scenarios e.g., investigators with wrongful intent, going to considerable lengths to re-identify genetic sequences they have agreed to use in a de-identified manner, by cross-linking to reference specimens that do not exist One sure way to eliminate risk  NO RESEARCH If we accept that research is a societal good, we accept that, by definition, some risk is acceptable… but are we obligated or justified in assuming the worst, in the absence of evidence that the worst is occurring… or is any more than a hypothetical?

“The national system for the protection of human research participants is indeed a system in jeopardy. The major source of the threat to its proper functioning is the increasing pressure to perform tasks that either do not require doing, could be done better by others, or could be done more efficiently using expedited review procedures.” Fost and Levine, JAMA, 2007